Research & Development

Since the beginning of our activities, the focus of Microbiológica has always been research and development of biologically active substances to address unmet medical needs.

In Brazil, our efforts have concentrated in contributing to the large national programs for the assistance of the most needy population. It was the case in the organ transplant program of the 80s and in the devastating AIDS epidemic of the 90s. In the latter case, as a result of our research in the structural transformations of nucleosides, we launched the so-called Brazilian AZT, which played an important role in the implementation of the National AIDS Program.

The case of lamivudine was our first challenge in the total, stereoselective synthesis of a complex nucleoside. It was a structuring project which opened the doors to other more ambitious, far-reaching projects, in Brazil and internationally.

Our research platform evolved into the discovery and development of other direct acting antiviral agents against HIV, hepB, and hepC viruses. These programs led us to the study of chemical transformations of abundant natural sugars for the evolution of the L-nucleosides (anti-hepB, L-thymidine, for example) and the branched nucleosides (anti-hepC, 2´-methylcytidine and 2´-methyl-2´-fluorouridine, a moiety present in sofosbuvir, which ushered a new era in the treatment and cure of hepC.)

The central role of sofosbuvir as the backbone of curative therapies of hepC, prompted us to establish in Brazil a large scale synthesis for this nucleotide prodrug.

Currently, Microbiológica is engaged in a program for the discovery of new nucleosides/nucleotides active against viruses of the Flaviviridae family which have emerged, in Brazil, as rather large public health threats. These include the search of active leads against ZIKAV, DENV, and yellow fever.

All and all, Microbiológica has gathered a considerable portfolio of documented synthetic procedures on small, medium, and large scale, under GMP conditions, leading to high quality APIs for human consumption.